Neurolief Receives Strategic Investment from BrainsWay for MDD Treatment.

Thursday, Aug 21, 2025 9:37 am ET1min read
BWAY--

Neurolief, a brain stimulation company, has received a strategic investment from BrainsWay Ltd., a global leader in non-invasive neurostimulation treatments for mental health disorders. This investment marks a significant milestone as Neurolief awaits FDA approval and prepares for the commercial launch of its ProlivRx, a treatment for Major Depressive Disorder. The partnership reflects a strategic alignment between the two companies, dedicated to expanding access to innovative mental health treatments.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet